hydrazine has been researched along with Blood Loss, Surgical in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bury, L; Gresele, P; Paciullo, F | 1 |
| Balduini, CL; Barozzi, S; Bozzi, V; Gresele, P; Pecci, A; Zaninetti, C | 1 |
| Bakshi, KK; Brainsky, A; Tarantino, MD | 1 |
| Balduini, CL; Barozzi, S; d'Amico, S; Pecci, A | 1 |
4 other study(ies) available for hydrazine and Blood Loss, Surgical
| Article | Year |
|---|---|
Eltrombopag to allow chemotherapy in a patient with MYH9-related inherited thrombocytopenia and pancreatic cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzoates; Blood Loss, Surgical; Endoscopy, Digestive System; Female; Humans; Hydrazines; Myosin Heavy Chains; Pancreatic Neoplasms; Platelet Count; Pyrazoles; Receptors, Thrombopoietin; Thrombocytopenia | 2020 |
Eltrombopag in preparation for surgery in patients with severe MYH9-related thrombocytopenia.
Topics: Benzoates; Blood Loss, Surgical; Female; Humans; Hydrazines; Male; Myosin Heavy Chains; Postoperative Hemorrhage; Pyrazoles; Thrombocytopenia; Treatment Outcome | 2019 |
Hemostatic challenges in patients with chronic immune thrombocytopenia treated with eltrombopag.
Topics: Adult; Aged; Benzoates; Blood Loss, Surgical; Blood Platelets; Chronic Disease; Clinical Trials, Phase II as Topic; Female; Humans; Hydrazines; Male; Middle Aged; Platelet Count; Postoperative Hemorrhage; Pyrazoles; Randomized Controlled Trials as Topic; Retrospective Studies; Surgical Procedures, Operative; Thrombocytopenia | 2014 |
Short-term eltrombopag for surgical preparation of a patient with inherited thrombocytopenia deriving from MYH9 mutation.
Topics: Adult; Benzoates; Bleeding Time; Blood Loss, Surgical; Coagulants; Drug Administration Schedule; Female; Genetic Predisposition to Disease; Heredity; Humans; Hydrazines; Molecular Motor Proteins; Mutation, Missense; Myosin Heavy Chains; Orthopedic Procedures; Phenotype; Postoperative Hemorrhage; Pyrazoles; Severity of Illness Index; Thrombocytopenia; Time Factors; Treatment Outcome | 2012 |